{"id":"vx-880","safety":{"commonSideEffects":[{"rate":null,"effect":"Unknown"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"VX-880 uses induced pluripotent stem cells (iPSCs) to generate retinal pigment epithelial cells, which are then transplanted into the retina to replace damaged cells and restore vision. This approach has shown promise in preclinical studies and is currently being investigated in clinical trials.","oneSentence":"VX-880 is a stem cell therapy that aims to restore vision in patients with advanced retinitis pigmentosa.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:40:58.356Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of advanced retinitis pigmentosa"}]},"trialDetails":[{"nctId":"NCT06832410","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-03-31","conditions":"Type 1 Diabetes, Kidney Transplant","enrollment":10},{"nctId":"NCT04786262","phase":"PHASE3","title":"A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-03-29","conditions":"Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zimislecel","Formerly known as STx-02"],"phase":"phase_3","status":"active","brandName":"VX-880","genericName":"VX-880","companyName":"Vertex Pharmaceuticals Incorporated","companyId":"vertex-pharmaceuticals-incorporated","modality":"Biologic","firstApprovalDate":"","aiSummary":"VX-880 is a stem cell therapy that aims to restore vision in patients with advanced retinitis pigmentosa. Used for Treatment of advanced retinitis pigmentosa.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}